| Dr John T Hart, MD | |
|
20925 Professional Plz, Suite 100, Ashburn, VA 20147-3403 | |
| (703) 724-9694 | |
| (703) 724-4017 |
| Full Name | Dr John T Hart |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 20925 Professional Plz, Ashburn, Virginia |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548383532 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VG0400X | Obstetrics & Gynecology - Gynecology | 0101058140 (Virginia) | Primary |
| 208D00000X | General Practice | 0101058140 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr John T Hart, MD 17201 Pickwick Dr, Purcellville, VA 20132-3141 Ph: (703) 724-9694 | Dr John T Hart, MD 20925 Professional Plz, Suite 100, Ashburn, VA 20147-3403 Ph: (703) 724-9694 |
News Archive
Recent years have provided substantial research displaying the effect of genetic mutations on the development of autism and other neurodevelopmental disorders.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that it has received three 2015 Hermes Creative Awards. These awards recognize the association for the exceptional writing and design of its news publications and website, which help laboratory medicine professionals worldwide stay informed about important issues in the field and find solutions to challenging patient health problems.
For the third straight year, Children's Hospital Los Angeles is ranked among the top five children's hospitals in the country, a distinction that recognizes the hospital's clinical expertise and the quality and breadth of its patient care.
LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company's lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations.
NormOxys Inc., a biotechnology company developing a novel class of small molecule drugs which enhance the body's ability to deliver oxygen to diseased tissues, today announced that it has initiated a Phase 1 clinical trial of OXY111A, a novel allosteric modulator of affinity of oxygen to hemoglobin. NormOxys plans to initially develop this compound as a treatment for chronic heart failure and cancer indications.
› Verified 3 days ago